Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
After finishing at $72.54 in the prior trading day, Avidity Biosciences Inc (NASDAQ: RNA) closed at $72.6, up 0.08%. In other words, the price has increased by $0.08 from its previous closing price. On the day, 1.16 million shares were traded. RNA stock price reached its highest trading level at $72.7 during the session, while it also had its lowest trading level at $72.42.
Ratios:
Our goal is to gain a better understanding of RNA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 11.57 and its Current Ratio is at 11.57. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In the most recent recommendation for this company, Roth Capital on September 17, 2025, initiated with a Buy rating and assigned the stock a target price of $62.
On June 24, 2025, Bernstein started tracking the stock assigning a Outperform rating and target price of $50.Bernstein initiated its Outperform rating on June 24, 2025, with a $50 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 07 ’26 when Boyce Sarah sold 8,576 shares for $72.23 per share. The transaction valued at 619,444 led to the insider holds 283,394 shares of the business.
Calderaro Charles III sold 3,727 shares of RNA for $269,201 on Jan 07 ’26. The Chief Technical Officer now owns 49,797 shares after completing the transaction at $72.23 per share. On Jan 07 ’26, another insider, McCarthy Teresa, who serves as the Chief Human Resources Officer of the company, sold 1,965 shares for $72.23 each. As a result, the insider received 141,932 and left with 116,867 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RNA now has a Market Capitalization of 10939059200 and an Enterprise Value of 9113189376. For the stock, the TTM Price-to-Sale (P/S) ratio is 524.41 while its Price-to-Book (P/B) ratio in mrq is 5.65. Its current Enterprise Value per Revenue stands at 436.706 whereas that against EBITDA is -14.963.
Stock Price History:
The Beta on a monthly basis for RNA is 0.93, which has changed by 1.5082989 over the last 52 weeks, in comparison to a change of 0.15507638 over the same period for the S&P500. Over the past 52 weeks, RNA has reached a high of $72.61, while it has fallen to a 52-week low of $21.51. The 50-Day Moving Average of the stock is 1.52%, while the 200-Day Moving Average is calculated to be 56.25%.
Shares Statistics:
The stock has traded on average 4.78M shares per day over the past 3-months and 2019580 shares per day over the last 10 days, according to various share statistics. A total of 146.77M shares are outstanding, with a floating share count of 138.08M. Insiders hold about 8.40% of the company’s shares, while institutions hold 95.47% stake in the company. Shares short for RNA as of 1767139200 were 8791796 with a Short Ratio of 1.84, compared to 1764288000 on 8865578. Therefore, it implies a Short% of Shares Outstanding of 8791796 and a Short% of Float of 5.88.
Earnings Estimates
As of right now, 11.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$1.28, with high estimates of -$0.98 and low estimates of -$1.59.
Analysts are recommending an EPS of between -$3.62 and -$5.16 for the fiscal current year, implying an average EPS of -$4.49. EPS for the following year is -$4.89, with 14.0 analysts recommending between -$3.24 and -$6.53.
Revenue Estimates
13 analysts predict $1.98M in revenue. The current quarter. It ranges from a high estimate of $12.5M to a low estimate of -$6.5M. As of. The current estimate, Avidity Biosciences Inc’s year-ago sales were $2.97M
A total of 13 analysts have provided revenue estimates for RNA’s current fiscal year. The highest revenue estimate was $30.4M, while the lowest revenue estimate was $5.4M, resulting in an average revenue estimate of $18.36M. In the same quarter a year ago, actual revenue was $10.9M
